2nd Abu Dhabi Brain Conference 2022 Program Book

FIRST AND ONLY CGRP ANTIBODY APPROVED FOR BOTH TREATMENT OF MIGRAINE PREVENTION AND EPISODIC CLUSTER HEADACHE 1 FOR MIGRAINE FOR EPISODIC CLUSTER HEADACHE Reference: 1. Emgality product information USPI. Scan the QR code for Abbreviated Prescribing Information For adverse events and safety reporting, please send an email: PV-MEA@lilly.com For further information about Lilly and Lilly products, please contact us at the below address: UAE: Bldg. 25 - 6th Floor, Dubai Health Care City, Dubai, UAE, P.O. Box #25319, Tel.: (+971 4) 453 7800, Fax: (+971 4) 436 2399 © 2022 Eli Lilly and Company. All Rights Reserved. PP-GZ-AE-0443